Skip to main content
SpringerLink
Log in

Expanding Indications for Defibrillators after Myocardial Infarction: Risk Stratification and Cost Effectiveness

  • Published:
Cardiac Electrophysiology Review

Abstract

Practice guidelines have expanded to include a new Class IIa recommendation for implantable cardiac defibrillator (ICD) use in patients post-myocardial infarction (MI) with a left ventricular ejection fraction (LVEF) ≤30% on the basis of the results of the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II). Given that over 3 million patients in North America meet these criteria and over 400,000 additional patients will meet these criteria every year, the potential costs to the healthcare system are substantial and possibly prohibitive. The results of MADIT II must be interpreted in the context of other studies. The benefits of ICD therapy may vary substantially across subgroups of MADIT II patients. Studies of amiodarone suggest that it may be useful if used in addition to beta-blockers, and the relative value of this therapy compared to ICD therapy remains to be elucidated. Subgroups of MADIT II patients with QRS duration >0.12 seconds or LVEF ≤25% appear to derive the greatest benefit from ICD therapy. Cost-effectiveness depends on the magnitude of benefit expected and will differ across subgroups of patients with different levels of risk. Better risk stratification strategies are needed to predict which patients will benefit most. Results of ongoing studies will be crucial in determining the relative effectiveness of ICD compared to optimal medical therapy including the use of amiodarone and beta-blockers. Predictors of subsets of MADIT II patients most likely to benefit from ICD therapy are urgently needed in order to prioritize allocation of healthcare resources.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.

    Google Scholar 

  2. Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, Kerber RE, Naccarelli GV, Schoenfeld MH, Silka MJ, Winters SL. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002; 106: 2145-2161.

    Google Scholar 

  3. Olshansky B, Loots D, McGrory-Usset M. Implantable cardioverter defibrillator pratices and costs at an academic medical center. J Cardiovasc Electrophysiol 2001; 12: 162-166.

    Google Scholar 

  4. Venditti FJ Jr, O'Connell M, Martin DT, Shahian DM. Transvenous cardioverter defibrillators: Cost implications of a less invasive approach. PACE 1995; 18: 711-715.

    Google Scholar 

  5. Greene HL, Richardson DW, Barker AH, Roden DM, Capone RJ, Echt DS, Friedman LM, Gillespie MJ, Hallstrom AP, Verter J and the CAPS Investigators. Classification of deaths after myocardial infarction as arrhythmic or non arrhythmic (the Cardiac Arrhythmia Pilot Study). Am J Cardiol 1989; 63: 1-6.

    Google Scholar 

  6. The Multicenter Post Infarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309: 331-336.

    Google Scholar 

  7. Bigger JT, Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM and the Multicenter Post Infarction Research Group. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the two years after myocardial infarction. Circulation 1984; 69: 250-258.

    Google Scholar 

  8. Steinberg JS, Regan A, Sciacca RR, Bigger JT Jr, Fleiss JL, Salvatore DE, Fosina M, Rolnitzky LM. Predicting arrhythmic events after acute myocardial infarction using the signal-averaged electrocardiogram. Am J Cardiol 1992; 69: 13-21.

    Google Scholar 

  9. Verschueren LJ. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability. J Am Coll Cardiol 1992; 19: 1369.

    Google Scholar 

  10. Bourke JP, Richards DAB, Ross DL, Wallace EM, McGuire MA, Uther JB. Routine programmed electrical stimulation in surviviors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow-up: Results, optimal stimulation protocol and costeffective screening. J Am Coll Cardiol 1991; 18: 780-788.

    Google Scholar 

  11. Eisenberg MJ. Risk stratification for arrhythmic events: Are the bangs worth the bucks? J Am Coll Cardiol 2001; 38: 1912-1915.

    Google Scholar 

  12. Farrell TG, Bashir Y, Cripps T, Malik M, Poloniecki J, Bennett ED, Ward DE, Camm AJ. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables, and signal-averaged electrocardiogram. J Am Coll Cardiol 1991; 18: 687-697.

    Google Scholar 

  13. McClements BM, Adgey AA. Value of signal-averaged electrocardiography, radionuclide ventriculography, Holter monitoring and clinical variables for prediction of arrhythmic events in survivors of acute myocardial infarction in the thrombolytic era. J Am Coll Cardiol 1993; 21: 1419-1427.

    Google Scholar 

  14. Hartikainen JEK, Malik M, Staunton A, Poloniecki J, Camm AJ. Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias, and left ventricular ejection fraction. J Am Coll Cardiol 1996; 28: 296-304.

    Google Scholar 

  15. Pedretti R, Etro MD, Laporta A, Braga SS, Caru B. Prediction of late arrhythmic events after acute myocardial infarction from combined use of noninvasive prognostic variables and inducibility of sustained monomorphic ventricular tachycardia. Am J Cardiol 1993; 71: 1131-1141.

    Google Scholar 

  16. El-Sherif N, Denes P, Katz R, Capone R, Mitchell LB, Carlson M, Reynolds-Haertle R. Definition of the best prediction criteria of the time domain signal-averaged electrocardiogram for serious arrhythmic events in the postinfarction period. J Am Coll Cardiol 1995; 25: 908-914.

    Google Scholar 

  17. Gomes JA, Winters SL, Stewart D, Horowitz S, Milner M, Barreca P. A new non-invasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction: Based on signal averaged electrocardiogram, radionuclide ejection fraction and Holter monitoring. J Am Coll Cardiol 1987; 10: 349-357.

    Google Scholar 

  18. Bailey JJ, Berson AS, Handelsman H, Hodges M. Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. J Am Coll Cardiol 2001; 38: 1902-1911.

    Google Scholar 

  19. Heidenreich PA, Lee TT, Massie BM. Effect of betablockade on mortality in patients with heart failure: A metaanalysis of randomized clinical trials. J Am Coll Cardiol 1997; 30: 27-34.

    Google Scholar 

  20. CIBIS-II Investigators and Committees. The Cardiac Insuffciency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9-13.

    Google Scholar 

  21. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.

    Google Scholar 

  22. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390.

    Google Scholar 

  23. Freemantle N, Cleland JG, Young P, Mason J, Harrison J. Beta-blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 2001; 318: 1730-1737.

    Google Scholar 

  24. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Metaanalysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350: 1417-1424.

    Google Scholar 

  25. Piepoli M, Villani GQ, Ponikowski P, Wright A, Flather MD, Coats AJS. Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure. International Journal of Cardiology 1998; 66: 1-10.

    Google Scholar 

  26. Boutitie F, Boissel JP, Connolly SJ, Camm AJ, Cairns JA, Julian DG, Gent M, Janse MJ, Dorian P, Frangin G, and the EMIAT and CAMIAT Investigators. Amiodarone interaction with b-blockers: Analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) Databases. Circulation 1999; 99: 2268-2275.

    Google Scholar 

  27. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P for the European Myocardial Infarct Amiodarone Trial Investigators. Randomised trial of effect of amiodarone on mortality in patients with leftventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-674.

    Google Scholar 

  28. Cairns JA, Connolly SJ, Roberts R, Gent M for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349: 675-682.

    Google Scholar 

  29. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted de-fibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933-1940.

    Google Scholar 

  30. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.

    Google Scholar 

  31. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the anti-arrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227-233.

    Google Scholar 

  32. Moss AJ. Implantable cardioverter defibrillator therapy: The sickest patients benefit the most. Circulation 2000; 101: 1638-1640.

    Google Scholar 

  33. Buxton AE, Lee KL, Fisher JD, Gold MR, Josephson ME, Prystowsky EN, Hafley G for the Multicenter Unsustained Tachycardia Trial Investigators. Arandomized study of the prevention of sudden death in patients with coronary disease. N Engl J Med 1999; 341: 1882-1890.

    Google Scholar 

  34. Lee KL, Fisher JD, Gold MR, Prystowsky EN, Talajic M, Josephson ME, Packer DL, Buxton AE for the Multicenter Unsustained Tachycardia Trial Investigators. Effect of implantable defibrillators on arrhythmic events and mortality in the Multicenter Unsustained Tachycardia Trial. Circulation 2002; 106: 233-238.

    Google Scholar 

  35. Bigger JT for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 1997; 337: 1569-1575.

    Google Scholar 

  36. Moss AJ, Hall WJ, Zareba W. Implantable cardiac defibrillators. N Engl J Med 2002; 347: 365-367 (Letter).

    Google Scholar 

  37. Raviele A, Bongiorni MG, Brignole M, Cappato R, Capucci A, Gaita F, Mangiameli S, Montenero A, Pedretti R, Salerno J, Sermasi S. Which strategy is “Best” after myocardial infarction? The Beta-blocker Strategy plus Implantable Cardioverter Defibrillator Trial: Rationale and study design. Am J Cardiol 1999; 83: 104D-111D.

    Google Scholar 

  38. Hohnloser SH, Connolly SJ, Kuck KH, Dorian P, Fain E, Hampton JR, Hatala R, Pauly AC, Roberts RS, Themeles E, Gent M for the DINAMIT Investigators. The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): Study protocol. Am Heart J 2000; 140: 735-739.

    Google Scholar 

  39. Klein H, Auricchio A, Reek S, Christoph Geller. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADITII. Am J Cardiol 1999; 83: 91D-97D.

    Google Scholar 

  40. Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, Marron R, Zou KH, Moss AJ for the MADIT Investigators. The cost-effectiveness of automatic implantable cardiac defibrillators: Results from MADIT Circulation 1998; 97: 2129-2135.

    Google Scholar 

  41. Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, Hlatky MA. Costeffectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med 1997; 126: 1-12.

    Google Scholar 

  42. Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, Owens DK. Potential costeffectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med 2001; 135: 870-883.

    Google Scholar 

  43. Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on costeffectiveness of the implantable cardioverter defibrillator. Am Heart J 2002; 144: 440-448.

    Google Scholar 

  44. Sheldon R, Connolly S, Krahn A, Roberts R, Gent M, Gardner M, on behalf of the CIDS Investigators. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: The Canadian Implantable Defibrillator Study. Circulation 2000; 101: 1660-1664.

    Google Scholar 

  45. Albert CM, Ma J, Rafai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105: 2595-2599.

    Google Scholar 

  46. Spooner PM, Zipes DP. Sudden death predictors: An inflammatory association. Circulation 2002; 105: 2574-2676.

    Google Scholar 

  47. Boriani G, Biffi M, Martignani C, Gallina M, Branzi A. Cost-effectiveness of implantable cardioverterdefibrillators. Eur Heart J 2001; 22: 990-996.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jewish General Hospital, McGill University, Montreal, Quebec, Canada

    Vidal Essebag & Mark J. Eisenberg

Authors
  1. Vidal Essebag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark J. Eisenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Essebag, V., Eisenberg, M.J. Expanding Indications for Defibrillators after Myocardial Infarction: Risk Stratification and Cost Effectiveness. Card Electrophysiol Rev 7, 43–48 (2003). https://doi.org/10.1023/A:1023639006565

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1023639006565

Search

Navigation